Abstract

Chronic subdural hematoma (SDH) is associated with trauma, antiplatelet therapy, anticoagulant medications, long-term alcohol abuse, arteriovenous malformations, and even postcraniotomy. However, SDH associated with imatinib mesylate (IM) treatment for chronic myeloid leukemia (CML) is rare that too in the remission phase of CML is even rarer. Among the cases of CML in remission phase, the literature review of those with SDH revealed that IM was taken in a dose of 800 mg per day. We report a case of SDH in a 70-year-old gentleman who was in the chronic remission phase of CML and was treated with IM 400 mg per day by hematologist.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.